Comparison of escitalopram and paroxetine in the treatment of major depressive disorder

International Clinical Psychopharmacology

Volumn 28, Issue 6, 2013, Pages 339-345

  Lin, Huang Li ^b   Hsu, Ya Ting ^a   Liu, Chia Yih ^b   Chen, Chia Hui ^a,g   Hsiao, Mei Chun ^b   Liu, Yu Li ^a,c,i   Shen, Winston W ^d   Hsiao, Chin Fu ^a   Liu, Shen Ing ^e   Chang, Liang Huey ^h   Tang, Hwa Sheng ^f   Lai, Hsiang Ling ^a   Lin, Pei Sheng ^a   Lin, Keh Ming ^a,j   Tsou, Hsiao Hui ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^h FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Depression; Efficacy; Escitalopram; Paroxetine

Indexed keywords

ESCITALOPRAM; LORAZEPAM; PAROXETINE; ZOLPIDEM;

ADULT; ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; BLURRED VISION; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; REMISSION; SCORING SYSTEM; SEXUAL BEHAVIOR; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYMPTOM ASSESSMENT; TAIWAN; TREATMENT RESPONSE; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84885324329     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32836458e2     Document Type: Article

References (35)

1. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I (2006a). A double-blind, randomized, parallel-group, flexible-Dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21:159-169
2. Baldwin DS, Huusom AK, Maehlum E (2006b). Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebocontrolled, double-blind study. Br J Psychiatry 189:264-272
3. Barbey JT, Roose SP (1998). SSRI safety in overdose. J Clin Psychiatry 59:42-48
4. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, et al. (2000). Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: Comparison of drug adherence. Cochrane Database Syst Rev 4:CD002791
5. Bielski RJ, Bose A, Chang CC (2005). A double-blind comparison of escitalopram and paroxetine in the long-Term treatment of generalized anxiety disorder. Ann Clin Psychiatry 17:65-69
6. Boulenger JP, Huusom AK, Florea I, Baekdal T, SarchiaponeM(2006). A comparative study of the efficacy of long-Term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 22:1331-1341
7. Boulenger JP, Hermes A, Huusom AK, Weiller E (2010). Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalopram vs. paroxetine. Curr Med Res Opin 26:605-614
8. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P (2008). Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 65:513-520
9. First MB, Spitzer RL, Gibbon M, Williams JB (1996). Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press Inc
10. Gale C (2007). Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder. Evid Based Ment Health 10:45
11. Gilmor ML, Owens MJ, Nemeroff CB (2002). Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 159:1702-1710
12. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, revised ed. Washington, DC: US Department of Health, Education, and Welfare
13. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
14. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
15. Henkel V, Seemuller F, Obermeier M, Adli M, Bauer M, Mundt C, et al. (2009). Does early improvement triggered by antidepressants predict response/ remissioñAnalysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115:439-449
16. Hirschfeld RM (2000). Antidepressants in long-Term therapy: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403:35-38
17. Hyttel J, Bogeso KP, Perregaard J, Sanchez C (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88:157-160
18. Kasper S, Baldwin DS, Larsson Lonn S, Boulenger JP (2009). Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsychopharmacol 19:229-237
19. Kessler RC, DuPont RL, Berglund P, Wittchen HU (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923
20. Kessler RC, Berglund PA, Dewit DJ, Ustun TB, Wang PS, Wittchen HU (2002). Distinguishing generalized anxiety disorder from major depression: Prevalence and impairment from current pure and comorbid disorders in the US and Ontario. Int J Methods Psychiatr Res 11:99-111
21. Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C (2007). Doubleblind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 27:481-492
22. Lin KM, Lau JK, Smith R, Phillips P, Antal E, Poland RE (1988a). Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology (Berl) 96:365-369
23. Lin KM, Poland RE, Lau JK, Rubin RT (1988b). Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 8: 195-201
24. Montgomery SA, Andersen HF (2006). Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 21:297-309
25. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329
26. Montgomery SA, Moller HJ (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 24:111-118
27. Moore N, Verdoux H, Fantino B (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20:131-137
28. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350
29. Rausch JL, Corley KM, Hobby HM (2004). Improved potency of escitalopram on the human serotonin transporter: Demonstration of an ex vivo assay technique. J Clin Psychopharmacol 24:209-213
30. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berl) 174:163-176
31. Stein DJ, Andersen EW, Lader M (2006). Escitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensions. Eur Neuropsychopharmacol 16:33-38
32. Szadoczky E, Rozsa S, Zambori J, Furedi J (2004). Predictors for 2-year outcome of major depressive episode. J Affect Disord 83:49-57
33. Wade A, Gembert K, Florea I (2007). A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 23:1605-1614
34. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. (1989). The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 262:914-919
35. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV (2007). Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 29: 2319-2332